Stocks of DaVita Inc. (NYSE:DVA) traded higher last session on Wall Street, up 1.75% to $78.50.
According to the data, DaVita Inc. (NYSE:DVA) has 8 analysts covering its stock. The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $84.00 and a low of $72.00, we find $76.00. Given the previous closing price of $77.15, this indicates a potential downside of -1.49 percent. DVA stock price is now 5.79% away from the 50-day moving average and -12.54% away from the 200-day moving average. The market capitalization of the company currently stands at $7.12B.
A total of 5 analysts have issued a hold rating and 0 have given it a buy rating. Brokers who have rated the stock have averaged $77.20 as their price target over the next twelve months.
With the price target reduced from $97 to $72, Deutsche Bank Downgraded its rating from Buy to Hold for DaVita Inc. (NYSE: DVA). On October 31, 2022, UBS Downgraded its previous ‘Buy’ rating to ‘Neutral’ on the stock reducing its target price from $117 to quote $74, while ‘BofA Securities’ rates the stock as ‘Underperform’.
In other news, NEHRA JOHN M, Director bought 5,000 shares of the company’s stock on Nov 01. The stock was bought for $355,675 at an average price of $71.14. Upon completion of the transaction, the Director now directly owns 15,000 shares in the company, valued at $1.18 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 23, Chief Operating Officer, DKC STAFFIERI MICHAEL DAVID bought 20,000 shares of the business’s stock. A total of $1,554,000 was incurred on buying the stock at an average price of $77.70. This leaves the insider owning 61,190 shares of the company worth $4.8 million. Insiders disposed of 255,413 shares of company stock worth roughly $20.05 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DVA stock. A new stake in DaVita Inc. shares was purchased by BALYASNY ASSET MANAGEMENT LLC during the first quarter worth $13,385,000. WOODLINE PARTNERS LP invested $9,348,000 in shares of DVA during the first quarter. In the first quarter, MARSHALL WACE, LLP acquired a new stake in DaVita Inc. valued at approximately $8,899,000. HRT FINANCIAL LP acquired a new stake in DVA for approximately $8,506,000. GREAT WEST LIFE ASSURANCE CO /CAN/ purchased a new stake in DVA valued at around $6,747,000 in the second quarter. In total, there are 711 active investors with 90.70% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $77.01 for DaVita Inc. (NYSE: DVA). During the past 12 months, DaVita Inc. has had a low of $65.28 and a high of $124.81. As of last week, the company has a debt-to-equity ratio of 17.05, a current ratio of 1.30, and a quick ratio of 1.20. The fifty day moving average price for DVA is $73.92 and a two-hundred day moving average price translates $89.58 for the stock.
The latest earnings results from DaVita Inc. (NYSE: DVA) was released for Jun, 2022. According to the Medical Care Facilities Company, earnings per share came in at $2.3, beating analysts’ expectations of $2.09 by 0.21. This compares to $2.91 EPS in the same period last year. The net profit margin was 5.80% and return on equity was 99.40% for DVA. The company reported revenue of $2.95 billion for the quarter, compared to $2.94 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 0.35 percent. For the current quarter, analysts expect DVA to generate $2.98B in revenue.
DaVita Inc.(DVA) Company Profile
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.